New exciting results for SNF472 in a uremic rat model allow to file the 9th patent of Sanifit

Adenine induced uremia in rats shares compatible biochemical and morphological features to End Stage Renal Disease (ESRD) patients. Treatment with intravenous SNF472 led to a reduction of  80% in aorta calcification and 85% inhibition in heart calcification.

SNF472, Sanifit’s leading drug candidate is about to start phase I clinical trials and the results from these study allowed to file the 9th family of patents of Sanifit.